期刊文献+

慢性阻塞性肺疾病患者死因构成及其生存时间的影响因素 被引量:28

Causes of chronic obstructive pulmonary disease-related death and influencing factors of survival time
原文传递
导出
摘要 目的 分析慢性阻塞性肺疾病(COPD)患者的死亡原因及影响其首次因COPD急性加重(AECOPD)住院后生存时间的危险因素.方法 检索2006年1月至2008年12月收治、病案首页的主要诊断或次要诊断为COPD(ICD-10编码为J40-J47)的495例患者的临床资料,对其中67例死亡患者的病例资料进行回顾性分析,由专科高年资医师重新审核,纠正错误分类后,按国际疾病分类ICD-10进行编码统计.采用直接死因的启动原因即根本死因进行全死因构成及顺位分析.查阅死亡病例首次因AECOPD住院的临床资料,计算首次住院后的生存时间,进行Cox回归生存分析.结果 67例死亡COPD患者,死亡前12个月内第一秒用力呼气量(FEV1)占预计值百分比中位数为34%.患者死因构成:呼吸系统疾病39例(5 8.2%);心脑血管疾病16例(23.9%);恶性肿瘤10例(14.9%);糖尿病1例(1.5%),自杀1例(1.5%).67例死亡患者中,13例直至死亡从未因AECOPD住院,其余54例死亡距离其首次因AECOPD住院后的生存时间为1~159个月,平均38个月.54例患者Cox回归分析结果表明,合并缺血性心脏病、合并重度肺动脉高压、年龄、体质指数(BMI)、血清C反应蛋白(CRP)水平是影响生存时间的独立危险因素(均P<0.05).结论 呼吸系统疾病是中-重度COPD患者主要的死亡原因,其次为心脑血管疾病和恶性肿瘤.合并缺血性心脏病、合并重度肺动脉高压、年龄、BMI、血清CRP水平是影响其首次因AECOPD住院后生存时间的独立危险因素. Objective To study the causes of chronic obstructive pulmonary disease (COPD)related death and influencing factors of survival time from first hospitalization due to acute exacerbation of chronic obstructive pulmonary disease (AECOPD).Methods All patients with a primary or secondary diagnosis of COPD (International Classification of Diseases (ICD)-10 Codes J40-J47) were continuously enrolled at our hospital from January 2006 to December 2008.A retrospective review was performed on the medical records of COPD patients who died during hospitalization.The causes of death were coded and analyzed according to the International Classification of Diseases (ICD) -10.The underlying causes of death were identified and ranked in order of prevalence.The medical records of first hospitalization due to AECOPD were reviewed.Retrospective analysis was performed for the clinical data.And Cox regression analysis was used to select the independent risk factors of influencing the survival time.Results Sixtyseven patients died during hospitalization.The median FEV1 (forced expiratory volume in 1 second percentage) was 34%.The causes of death in the COPD inpatients were as follows:respiratory diseases ( n = 39),cardiocerebrovascular diseases ( n = 16),malignant tumors ( n = 10),diabetes mellitus ( n = 1 )and suicide (n = 1 ).Among them,54 patients had a history of hospitalization due to AECOPD.Thirteen deceased patients were never hospitalized because of AECOPD.The mean interval between the first admission with AECOPD as the primary diagnosis and death was 38 months (range:1 - 159).The independent risk factorsof influencing the survival time were as follows:complications with coronary artery disease & severe pulmonary hypertension,age,body mass index ( BMI ) and serum level of C-reactive protein (CRP) (all P 〈0.05) .Conclusion The major cause of death in moderate-severe COPD patients is respiratory disease.complicated with coronary artery disease & severe pulmonary hypertension,age,BMI and serum level of CRP are the independent risk factors of affecting the survival time from first hospitalization due to AECOPD.
出处 《中华医学杂志》 CAS CSCD 北大核心 2011年第12期824-827,共4页 National Medical Journal of China
基金 中华医学会临床医学科研专项资金项目(07010440052)
关键词 肺疾病 慢性阻塞性 死亡原因 生存时间 Pulmonary disease,chronic obstructive Cause of death Survival time
  • 相关文献

参考文献14

  • 1Lopez AD,Shibuya K,Rao C,et al.Chronic obstructive pulmonary disease:current burden and future projections.Eur Respir J,2006,27:397-412.
  • 2慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8237
  • 3McGarvey LP,John M,Anderson JA,et al.Ascertainment of cause-specific mortality in COPD:operations of the TORCH Clinical Endpoint Committee.Thorax,2007,62:411-415.
  • 4Charlson ME,Pompei P,Ales KL,et al.A new method of classifying prognostic comorbidity in longitudinal studies:development and validation.J Chronic Dis,1987,40:373-383.
  • 5Sundararajan V,Henderson T,Perry C,et al.New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality.J Clin Epidemiol,2004,57:1288-1294.
  • 6Rodríguez-Roisin R,Soriano JB.Chronic obstructive pulmonary disease with lung cancer and/or cardiovascular disease.Proc Am Thorac Soc,2008,5:842-847.
  • 7Hansell AL,Walk JA,Soriano JB.What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis.Eur Respir J,2003,22:809-814.
  • 8Calverley PM,Anderson JA,Celli B,et al.Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.N Engl J Med,2007,356:775-789.
  • 9Sin DD,Anthonisen NR,Soriano JB,et al.Mortality in COPD:Role of comorbidities.Eur Respir J,2006,28:1245-1257.
  • 10Feinleib M,Rosenberg HM,Collins JG,et al.Trends in COPD morbidity and mortality in the United States.Am Rev Respir Dis,1989,140:S9-S18.

二级参考文献21

  • 1有创-无创序贯机械通气多中心研究协作组.以肺部感染控制窗为切换点行有创与无创序贯机械通气治疗慢性阻塞性肺疾病所致严重呼吸衰竭的随机对照研究[J].中华结核和呼吸杂志,2006,29(1):14-18. 被引量:280
  • 2Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J, 2008, 32:1371-1385.
  • 3Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2005, 172: 189-194.
  • 4Peinado VI, Pizarro S, Barbera JA. Pulmonary vascular involvement in COPD. Chest, 2008, 134:808-814.
  • 5Carratu P, Scoditti C, Maniscalco M, et al. Exhaled and arterial levels of endothelin-1 are increased and correlate with pulmonary systolic pressure in COPD with pulmonary hypertension. BMC Pulm Med, 2008, 8:20.
  • 6Joppa P, Petrasova D, Stancak B, et al. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest, 2006, 130: 326-333.
  • 7Peinado VI, Ramirez J, Roca J, et al. Identification of vascular progenitor cells in pulmonary arteries of patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol, 2006, 34:257-263.
  • 8Morrell NW, Higham MA, Phillips PG, et al. Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease. Respir Res, 2005, 6:88.
  • 9Alp S, Skrygan M, Schmidt WE, et al. Sildenafil improves hemodynamic parameters in COPD-an investigation of six patients. Pulm Pharmacol Ther, 2006, 19:386-390.
  • 10Holverdaa S, Rietemaa H, Bogaard HJ, et al. Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD. Pulm Pharmacol Ther, 2008, 21:558-564.

共引文献8256

同被引文献227

引证文献28

二级引证文献330

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部